Cost of machinery, facility, electricity, etc.
Requires skilled workers
Whole plants take 6-12 weeks to flower
Yields are limited
Uses large amounts of space and natural resources
Variations and contaminations in the environment make plants impossible to standardize
ReaGenics is pioneering a novel plant cell bioreactor process for the mass-scale multiplication of cannabinoids. This eliminates the need to grow plants on an industrial scale for pharma-grade, botanically- derived cannabinoids. Leveraging success with patented technology for multiplication and manipulation of lavender cells, ReaGenics is applying the same technology to cannabis, allowing for consistent, controllable, and patentable formulations.
ReaGenics anticipates production periods up to four times faster and projected costs considerably cheaper, than plant cultivation. Creating powdered biomass for active pharmaceutical ingredients or extracted to produce cannabinoid oils, Bio-Reactor Production will change the way we look at medical cannabis.
ReaGenics is an Israeli based company, with founders from Poland and Israel, bring the best IP to the most dynamic cannabis ecosystem. Conceived at CannaTech 2018, ReaGenics was founded in Israel to conduct research and development related to cannabis production technologies.
The company was founded by Rafal Slusarczyk, a Polish entrepreneur and biologist, and iCAN: Israel Cannabis, a globally recognized leader in the cannabis industry. iCAN CEO, Saul Kaye, is a pharmacist and entrepreneur and board member on ReaGenics.
-Irritable bowel disease (IBD) formulation
-Formulations for other medical conditions to be determined in collaboration with expert physicians.
Co-founder, Rafal Slusarczyk, won sponsorship from the European Union as a participant in the Erasmus for Young Entrepreneurs program. He is the first member of the program in Israel.
We are always on the lookout for investors and collaborators.